



ABB10010P0470US (OZ-50761)

1614.
11/25/03
RECEIVED
TECH CENTER 1000
OCT 22 2003
10012900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application Of:

) Benzodiazepine Derivatives, the Production
) and Use Thereof

Lubisch et al.

)

Serial No.: 10/088,604

) Group Art Unit: 1614

Filed: July 1, 2002

) Examiner: Bruck Kifle

RESPONSE TO RESTRICTION REQUIREMENT

Commissioner for Patents
BOX RESPONSES NO-FEE
Alexandria, Virginia 22313-1450

Sir:

In response to the Restriction Requirement dated September 23, 2003, Applicants

elect Group II (compounds and uses of Formula (I) where A is C₂) with traverse.

Applicants traverse this Restriction Requirement on the grounds that there is a "single structural element that is shared by all of the alternatives", i.e., the compounds are all benzodiazepine derivatives and they also have the same utility.

Reconsideration of this Restriction Requirement is respectfully requested.

Respectfully submitted,

WOOD, PHILLIPS, KATZ, CLARK & MORTIMER



Martin L. Katz, Reg. No. 25,011

Date: October 17, 2003

Citicorp Center
500 West Madison Street
Suite 3800
Chicago, IL 60661
(312) 876-1800



ABB10010P0470US (OZ-50761)

37 CFR 1.8
CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service, as first class mail in an envelope addressed to Commissioner for Patents, Box No-Fee, Alexandria, Virginia 22313-1450 on October 17, 2003.

Rebecca J. Willis
Rebecca J. Willis